Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Educational leadership during a decade of medical curricular innovation and renewal.

Pinder KE, Shabbits JA.

Med Teach. 2018 Jun;40(6):578-581. doi: 10.1080/0142159X.2018.1440079. Epub 2018 Mar 5.

PMID:
29504442
2.

A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131.

Gelmon KA, Stewart D, Chi KN, Chia S, Cripps C, Huan S, Janke S, Ayers D, Fry D, Shabbits JA, Walsh W, McIntosh L, Seymour LK.

Ann Oncol. 2004 Jul;15(7):1115-22.

PMID:
15205207
3.

Integrin-linked kinase (ILK) in combination molecular targeting.

Edwards LA, Shabbits JA, Bally M, Dedhar S.

Cancer Treat Res. 2004;119:59-75. Review. No abstract available.

PMID:
15164873
4.

High ceramide content liposomes with in vivo antitumor activity.

Shabbits JA, Mayer LD.

Anticancer Res. 2003 Sep-Oct;23(5A):3663-9.

PMID:
14666662
5.

Tumor chemosensitization strategies based on apoptosis manipulations.

Shabbits JA, Hu Y, Mayer LD.

Mol Cancer Ther. 2003 Aug;2(8):805-13. Review. No abstract available.

6.

Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro.

Shabbits JA, Mayer LD.

Biochim Biophys Acta. 2003 May 2;1612(1):98-106.

7.
9.

Molecular and pharmacological strategies to overcome multidrug resistance.

Shabbits JA, Krishna R, Mayer LD.

Expert Rev Anticancer Ther. 2001 Dec;1(4):585-94. Review.

PMID:
12113091
10.

The role for liposomal drug delivery in molecular and pharmacological strategies to overcome multidrug resistance.

Mayer LD, Shabbits JA.

Cancer Metastasis Rev. 2001;20(1-2):87-93. Review.

PMID:
11831652

Supplemental Content

Loading ...
Support Center